Sugi Predict

Sugi Predict / Compounds / SCHEMBL4978331

SCHEMBL4978331

SCHEMBL4978331

O=C(Nc1ccc(Cl)cc1)c1c(Cl)cccc1NCc1ccncc1

nearest known ligand 0.61

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 10/20 0.61
▸ FLT1 P17948 6/20 0.60
▸ TYK2 P29597 4/20 0.59
▸ JAK1 P23458 3/20 0.59
▸ JAK2 O60674 2/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ NAMPT P43490 3/20 0.54
▸ MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4976745 0.88 KDR (0.59) KDRFLT1TYK2NAMPTMAPK1
SCHEMBL30846489 0.83 KDR (0.71) KDRFLT1NAMPT
SCHEMBL3005186 0.83 KDR (0.71) KDRFLT1NAMPT
SCHEMBL427598 0.81 KDR (0.68) KDRFLT1NAMPTMAPK1
SCHEMBL4974383 0.79 KDR (0.58) KDRFLT1TYK2NAMPT
SCHEMBL429479 0.78 KDR (0.66) KDRFLT1TYK2JAK1JAK2
SCHEMBL4980482 0.78 KDR (0.64) KDRFLT1TYK2JAK1JAK2
SCHEMBL4980301 0.78 KDR (0.64) KDRFLT1TYK2JAK1JAK2
SCHEMBL27486255 0.77 ADRA2C (0.51) KDRFLT1TYK2NAMPT
SCHEMBL429443 0.76 KDR (1.00) KDRFLT1NAMPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2004-10-07 — — US claimed
CN-1152014-C N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors ��˹��ŵ�� 2004-06-02 — — CN claimed
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2003-04-03 — — US claimed
US-6448277-B2 ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS NOVARTIS AG (CH) 2002-09-10 — — US claimed
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-02-14 — — US claimed
CN-1331680-A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-01-16 — — CN claimed
US-20080085902-A1 Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent BOLD GUIDO 2008-04-10 — — US disclosed
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ 2006-04-06 — — US disclosed
US-7002022-B2 N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF NOVARTIS AG (CH) 2006-02-21 — — US disclosed
US-6878720-B2 VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2005-04-12 — — US disclosed
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2004-10-07 — — US disclosed
CN-1152014-C N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors ��˹��ŵ�� 2004-06-02 — — CN disclosed
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2003-04-03 — — US disclosed
US-6448277-B2 ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS NOVARTIS AG (CH) 2002-09-10 — — US disclosed
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-02-14 — — US disclosed
CN-1331680-A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-01-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085902-A1 Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent VEGFA, FLT1, FLT4 KDR 4/4885FLT1 2/4885TYK2 3401/4885
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 KDR 4/4885FLT1 6/4885TYK2 198/4885
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NR2E3, AXL, FLT1 KDR 6/4885FLT1 3/4885TYK2 112/4885
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, KDR KDR 3/4885FLT1 6/4885TYK2 192/4885
US-20040198782-A1 N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 KDR 4/4885FLT1 6/4885TYK2 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.